{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:41:22Z","timestamp":1793173282226,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hungarian Diabetes Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: In the last couple of years, pharmacological management of patients with type 2 diabetes mellitus (T2DM) have been markedly renewed. The aim of this study was to analyse the changes in prescribing patterns of antidiabetic drugs for treating patients with T2DM in Hungary between 2015 and 2020. Material and Methods: In this retrospective, nationwide analysis, we used the central database of the National Health Insurance Fund. We present annual numbers and their proportion of T2DM patients with different treatment regimens. Results: In the period of 2015\u20132020, the number of incident cases decreased from 60,049 to 29,865, while prevalent cases increased from 682,274 to 752,367. Patients with metformin (MET) monotherapy had the highest prevalence (31% in 2020). Prevalence of insulin (INS) monotherapy continuously but slightly decreased from 29% to 27% while that of sulfonylurea (SU) monotherapy markedly decreased from 37% to 20%. Dipeptidyl peptidase (DPP-4) inhibitors remained popular in 2020 as monotherapy (5%), in dual combination with MET (12%) and in triple combination with MET and SU (5%). The prevalence of patients with sodium-glucose co-transporter-2 (SGLT-2) inhibitors increased from 1% to 4% in monotherapy, from &lt;1% to 6% in dual combination with MET, and from &lt;1% to 2% in triple oral combination with MET and SU or DPP-4-inhibitors. The prevalence of patients using glucagon-like peptide-1 receptor agonists (GLP-1-RAs) also increased but remained around 1\u20132% both in monotherapy and combinations. For initiating antihyperglycaemic treatment, MET monotherapy was the most frequently used regime in 2020 (50%), followed by monotherapy with SUs (16%) or INS (10%). After initial MET monotherapy, the incidence rates of patients with add-on GLP-1-RAs (2%, 3%, and 4%) and those of add-on SGLT-2 inhibitors (4%, 6%, and 8%) slowly increased in the subsequent 24, 48, and 72 months, respectively. Conclusions: In the period of 2015\u20132020, we documented important changes in trends of antihyperglycaemic therapeutic patterns in patients with T2DM which followed the new scientific recommendations but remained below our expectations regarding timing and magnitude. More efforts are warranted to implement new agents with cardiovascular\/renal benefits into therapeutic management in time, in a much larger proportion of T2DM population, and without delay.<\/jats:p>","DOI":"10.3390\/medicina58101382","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T04:00:02Z","timestamp":1665288002000},"page":"1382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020\u2014Nationwide Data from a Register-Based Analysis"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-7831","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Jermendy","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Bajcsy-Zsilinszky Teaching Hospital and Outpatient Clinic, Magl\u00f3di \u00fat 89-91, 1106 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kiss","sequence":"additional","affiliation":[{"name":"Nephrology-Diabetes Center, 2nd Department of Internal Medicine, Faculty of Medicine, University of P\u00e9cs, Pacsirta \u00fat 1, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Rokszin","sequence":"additional","affiliation":[{"name":"RxTarget Ltd., Bacs\u00f3 N\u00e1ndor utca 10, 5000 Szolnok, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Abonyi-T\u00f3th","sequence":"additional","affiliation":[{"name":"RxTarget Ltd., Bacs\u00f3 N\u00e1ndor utca 10, 5000 Szolnok, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Lengyel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Szeged, K\u00e1lv\u00e1ria sgt. 57, 6725 Szeged, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kempler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Kor\u00e1nyi S\u00e1ndor \u00fat 2, 1082 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-5733","authenticated-orcid":false,"given":"Istv\u00e1n","family":"Wittmann","sequence":"additional","affiliation":[{"name":"Nephrology-Diabetes Center, 2nd Department of Internal Medicine, Faculty of Medicine, University of P\u00e9cs, Pacsirta \u00fat 1, 7624 P\u00e9cs, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"ref_1","unstructured":"(2022, July 17). IDF Diabetes Atlas\u20149th Edition. Available online: www.diabetesatlas.org."},{"key":"ref_2","unstructured":"(2022, July 17). IDF Diabetes Atlas\u201410th Edition. Available online: www.diabetatlas.org."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/dme.12716","article-title":"Prevalence and incidence of diabetes mellitus: A nationwide population-based pharmaco-epidemiological study in Sweden","volume":"32","author":"Jansson","year":"2015","journal-title":"Diabet. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e010210","DOI":"10.1136\/bmjopen-2015-010210","article-title":"Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: A retrospective cohort study","volume":"6","author":"Sharma","year":"2016","journal-title":"BMJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00125-016-3971-y","article-title":"Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: A nationwide study in Sweden, 2006\u20132013","volume":"59","author":"Norhammar","year":"2016","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107788","DOI":"10.1016\/j.diabres.2019.107788","article-title":"Decreasing incidence of pharmacologically treated Type 2 diabetes in Hungary from 2001 to 2016: A nationwide cohort study","volume":"155","author":"Jermendy","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S2213-8587(20)30402-2","article-title":"Trends in the incidence of diagnosed diabetes: A multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings","volume":"9","author":"Magliano","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.12000","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Norton","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11892-016-0744-4","article-title":"Novel therapeutics for diabetes: Uptake, usage trends, and comparative effectiveness","volume":"16","author":"Ahuja","year":"2016","journal-title":"Curr. Diab. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjmed.2017.04.004","article-title":"Pharmacologic management of type 2 diabetes mellitus: Available therapies","volume":"130","author":"Thrasher","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1556\/650.2017.30769","article-title":"Trends in antidiabetic treatment prescribed for patients with type 2 diabetes in Hungary between 2001 and 2014\u2014Results from the database analysis of the National Health Insurance Fund","volume":"158","author":"Jermendy","year":"2017","journal-title":"Orv. Hetil."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1403494811404279","article-title":"Register-based studies of diabetes","volume":"39","author":"Carstensen","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/dme.14117","article-title":"Use of glucose-lowering drugs in Hungary between 2008 and 2017: The increasing use of novel glucose-lowering drug groups","volume":"36","author":"Csatordai","year":"2019","journal-title":"Diabet. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"G\u0119ca, T., Wojtowicz, K., Guzik, P., and G\u00f3ra, T. (2022). Increased risk of COVID-19 in patients with diabetes mellitus\u2014Current challenges in pathophysiology, treatment and prevention. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19116555"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40292-022-00524-7","article-title":"Telemedicine for the clinical management of diabetes; implications and considerations after COVID-19 experience","volume":"29","year":"2022","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_19","first-page":"119","article-title":"Clinical Practice Guideline\u2014Diagnosis of diabetes, and antihyperglycaemic treatment and care of patients with diabetes in adulthood","volume":"28","author":"Jermendy","year":"2020","journal-title":"Diabetol. Hung."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: Historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: A systematic review and an updated meta-analysis","volume":"18","author":"Han","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.trecan.2021.03.001","article-title":"Therapeutic repurposing of biguanides in cancer","volume":"7","author":"Zhao","year":"2021","journal-title":"Trends Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence","volume":"60","author":"DeCensi","year":"2017","journal-title":"Diabetologia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4239\/wjd.v11.i8.351","article-title":"Interstitial lung disease and diabetes","volume":"11","author":"Rajasurya","year":"2020","journal-title":"World J. Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lee, C.B., Chae, S.U., Jo, S.J., Jerng, U.M., and Bae, S.K. (2021). The relationship between the gut microbiome and metformin as a key for treating type 2 diabetes mellitus. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073566"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"645194","DOI":"10.3389\/fendo.2021.645194","article-title":"The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: A systematic review","volume":"12","author":"Zangiabadian","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.tem.2019.07.015","article-title":"Metformin as anti-aging therapy: Is it for everyone?","volume":"30","author":"Soukas","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/BF00401417","article-title":"The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work?","volume":"35","author":"Henquin","year":"1992","journal-title":"Diabetologia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/dom.14102","article-title":"Positioning sulfonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European Consensus Panel","volume":"22","author":"Consoli","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.jcjd.2021.03.002","article-title":"Insulin therapy: The discovery that shaped a century","volume":"45","author":"Gerstein","year":"2021","journal-title":"Can. J. Diabetes"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2337\/diab.43.3.396","article-title":"Lys(B28), Pro(B29)-human insulin: A rapidly absorbed analog of human insulin","volume":"43","author":"Howey","year":"1994","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12933-021-01281-y","article-title":"From glucose lowering agents to disease\/diabetes modifying drugs: A \u201cSIMPLE\u201d approach for the treatment of type 2 diabetes","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1556\/650.2019.31488","article-title":"De-escalation of antihyperglycemic treatment in patients with type 2 diabetes\u2014When less is more","volume":"160","author":"Jermendy","year":"2019","journal-title":"Orv. Hetil."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13300-022-01222-2","article-title":"Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes","volume":"13","author":"Jude","year":"2022","journal-title":"Diabetes Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4239\/wjd.v13.i2.85","article-title":"Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment","volume":"13","author":"Florentin","year":"2022","journal-title":"World J. Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.24121\/dh.2020.6","article-title":"DPP-4-inhibitors for treating patients with type 2 diabetes\u2014Updated guidelines, changing clinical practice","volume":"28","author":"Jermendy","year":"2020","journal-title":"Diabetol. Hung."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Janez, A., Muzurovic, E., Stoian, A.P., Haluzik, M., Guja, C., Czupryniak, L., Duvnjak, L., Lalic, N., Tankova, T., and Bogdanski, P. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. Int. J. Cardiol., 2022.","DOI":"10.1016\/j.ijcard.2022.07.017"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-021-01344-0","article-title":"CAPTURE: A multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries","volume":"20","author":"Mosenzon","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/dom.13088","article-title":"Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review","volume":"20","author":"Khunti","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(19)32131-2","article-title":"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial","volume":"394","author":"Matthews","year":"2019","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s13300-020-00881-3","article-title":"Clinical efficacy of quadruple oral therapy for type 2 diabetes in real-world practice: A retrospective observational study","volume":"11","author":"Cho","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e000059","DOI":"10.1136\/bmjdrc-2014-000059","article-title":"Durability of oral hypoglycemic agents in drug na\u00efve patients with type 2 diabetes: Report from the Swedish National Diabetes Register (NDR)","volume":"3","author":"Svensson","year":"2015","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.diabres.2016.06.018","article-title":"The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database","volume":"118","author":"Liatis","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Roberto, G., Barone-Adesi, F., Giorgianni, F., Pizzimenti, V., Ferrajolo, C., Tari, M., Bartolini, C., Da Cas, R., Maggini, M., and Spila-Alegiani, S. (2019). Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas. BMC Endocr. Disord., 19.","DOI":"10.1186\/s12902-019-0334-y"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3389\/fphar.2019.00870","article-title":"Treatment patterns of diabetes in Italy: A population-based study","volume":"10","author":"Menditto","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/dom.13877","article-title":"Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study","volume":"22","author":"Bang","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e14770","DOI":"10.1111\/ijcp.14770","article-title":"Drug utilisation study of antidiabetic medication during 2012\u20132019 in Romania","volume":"75","author":"Bucsa","year":"2021","journal-title":"Int. J. Clin. Pract."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/10\/1382\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:45:20Z","timestamp":1760143520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/10\/1382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["medicina58101382"],"URL":"https:\/\/doi.org\/10.3390\/medicina58101382","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}